Sbir phase II: bacteriophage-based microbial gene therapy platform for in situ engineering of microbiomes
Ended Cooperative Agreement Awarded Last action
- Award ID
- 2126838
- Recipient
-
Vulcan Biologics Inc. UEI LNBVDMU2KNN5
- Awarding agency
-
Division of Industrial Innovation
National Science Foundation
- Obligated
- $989,854
Award facts
- Assistance listing
- 47.041 Engineering
- Completion date
- Place of performance
- Irvine, CA 92617, USA
Award details come from USAspending.gov.
About this award
Vulcan Biologics Inc. received a $989,854 cooperative agreement award from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041) to support the development of a bacteriophage-based microbial gene therapy platform for in situ engineering of microbiomes. This project will leverage bacteriophages to deliver targeted genetic modifications within complex microbial communities, with the goal of engineering the function and composition of microbiomes in situ for applications such as environmental remediation, agriculture, and human health. The two-year award period runs from December 2021 through November 2023 and will support the company's efforts to advance this bacteriophage-based gene therapy platform technology.
Quick answers
Who received award 2126838?
2126838 was awarded to Vulcan Biologics Inc. by Division of Industrial Innovation (National Science Foundation) on December 15, 2021.
How much is award 2126838 worth?
$989,854 has been obligated on 2126838.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award